Objective: To establish a full-process management model for liver cancer patients undergoing interventional therapy based on the Patient Journey Map (PJM), and to evaluate its application effect. Methods: A non-synchronous controlled trial design was adopted. 120 liver cancer patients who underwent transcatheter arterial chemoembolization (TACE) in the Department of Infection of our hospital from January 2025 to December 2025 were selected. The control group included 60 patients (1–6 months) who received routine care, while the experimental group included 60 patients (7–12 months) who received the full-process management based on the Patient Journey Map. Through semi-structured interviews, the key touchpoints and needs of patients were clarified, and the Patient Journey Map was drawn. A three-stage full-process management plan of “hospitalization period - discharge preparation period - home rehabilitation period” was constructed. The satisfaction of patients, the incidence of postoperative complications, self-management ability, quality of life, and readmission rate were compared between the two groups. Results: The satisfaction rate of patients in the experimental group (96.67%) and the total score of self-management ability (86.35 ± 5.21) and the total score of quality of life (78.56 ± 6.42) were all higher than those in the control group (81.67%, 72.48 ± 6.35, 65.32 ± 7.18), respectively; the incidence of complications (13.33%) and the 30-day readmission rate (6.67%) were lower than those in the control group (30.00%, 18.33%), and the differences were statistically significant (P < 0.05). Conclusion: The full-process management model based on the Patient Journey Map can improve the satisfaction of liver cancer patients undergoing interventional therapy, reduce the incidence of complications and readmission rate, and improve self-management ability and quality of life, and has clinical application value.